Biotene Mouthwash

Phase 2

UUniversity of California, Los Angeles

Biotene Mouthwash is one of 16 therapeutic programs targeting Gonorrhea. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

GonorrheaCompleted

GonorrheaPhase 2

Completed

Competition

Competitive Landscape

19 competitors in Gonorrhea

#DrugCompanyPhaseTrials

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 2

Cipro

Garamycin

1 4

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

—5

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—6

Rocephin

CConrado Roberto Hoffmann Filho

Phase 3

4 7

Factive

LLG Chem

Approved

1 8

Azactam

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 9

Blujepa

GGlaxo Dba Glaxosmithkline

Phase 3

1 10

Delafloxacin

MMelinta Therapeutics, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gonorrhea1 trial

A Randomized Crossover Study to Evaluate the Efficacy of Antibacterial Mouthwash in Preventing Pharyngeal Gonorrhea Among a High Risk Population

Completed·UUniversity of California, Los Angeles·Phase 2·NCT04966507·89 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Biotene Mouthwash. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Biotene Mouthwash. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of California, Los Angeles company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: UUniversity of California, Los Angeles

Biotene Mouthwash

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Gonorrhea1 trial

References

Drug Info

Quick Facts

Related News